-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Acute Lymphocytic...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Analyst Opinions
Non-Alcoholic Beverages Demand Spaces and Top Trends – Industry Insights
Non-Alcoholic Beverages Demand Spaces and Top Trends Report Overview In the market for non-alcoholic beverages (NABs), consumers are influenced by global trends to seek more personalized, functional, and innovative products that will satisfy their demands on a more sensory level. The non-alcoholic beverages demand spaces and the top trends report explores the trend-sight overview such as setting the bar low, not going out, picking premium, and others. This report helps the market players, non-alcoholic beverages operators, to understand consumer needs...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Propagermanium in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Propagermanium in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Propagermanium in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in Diffuse Large B-Cell Lymphoma Drug Details: LP-284...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in Solid Tumor Drug Details: LP-284 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in Mantle Cell Lymphoma Drug Details: LP-284 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in B-Cell Non-Hodgkin Lymphoma Drug Details: LP-284 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...